Novità scientifiche — 11 Settembre 2026
Aggiornamenti scientifici verificati da MBC. Questa pagina contiene esclusivamente elementi acquisiti da fonti documentali tracciabili dopo il radar scientifico giornaliero. L’AI può indicare termini da controllare, ma il suo testo non viene pubblicato come fonte e non determina conclusioni cliniche.
Le informazioni sono presentate a fini documentali e non costituiscono una raccomandazione terapeutica, una previsione di efficacia o una valutazione di idoneità individuale.
Trial e studi clinici
- A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. · Luglio 24, 2026
NCT: NCT06247995
Fonte documentale originale ↗ - [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer · Luglio 6, 2026
NCT: NCT05870579
Fonte documentale originale ↗ - Aptamer-functionalized luteolin-loaded albumin nanoplatform for targeted therapy of HER2-positive breast cancer · Settembre 1, 2026
DOI: 10.1016/j.colsurfa.2026.141749
Fonte documentale originale ↗ - Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial · Settembre 11, 2026
DOI: 10.1200/jco-26-00602
Fonte documentale originale ↗ - 70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: outcome in the MINDACT trial for key clinical-pathological high-risk subgroups · Settembre 1, 2026
DOI: 10.1016/j.ejca.2026.117044
Fonte documentale originale ↗ - Hybrid cell membrane-functionalized biomimetic nanozymes: Triple-modal CDT/PTT/PDT therapy activates apoptosis, ferroptosis, pyroptosis, and cuproptosis to eliminate breast cancer · Settembre 1, 2026
DOI: 10.1016/j.matdes.2026.117014
Fonte documentale originale ↗
Nuova documentazione
- ОЦЕНКА ЛЕЧЕБНОГО ПОЛИХИМИОТЕРАПИИ ПРИ РАКЕ МОЛОЧНОЙ ЖЕЛЕЗЫ · Agosto 26, 2026
DOI: 10.66073/researchfocus.v2i1.2825
Fonte documentale originale ↗ - First case report of dual ‘double-hit’ malignancy in an axillary lymph node: When metastatic breast cancer collides with marginal zone lymphoma · Agosto 1, 2026
DOI: 10.1016/j.cpccr.2026.100443
Fonte documentale originale ↗ - USP10 is associated with TUBA1B protein stability, PI3K/AKT phosphorylation changes, and progression of triple-negative breast cancer · Settembre 1, 2026
DOI: 10.1016/j.prp.2026.156683
Fonte documentale originale ↗ - Deciphering the origin and plasticity of circulating endothelial cells reveals a systemic angiogenic program in breast cancer · Novembre 3, 2025
DOI: 10.1182/blood-2025-1324
Fonte documentale originale ↗ - Explainable machine learning for breast cancer prediction in resource-constrained settings: A multi-algorithmic framework integrating shap-based transparency with clinical decision support · Settembre 11, 2026
DOI: 10.1371/journal.pdig.0001706
Fonte documentale originale ↗ - Targeted axillary dissection using Magseed magnetic bead in female patients with breast cancer · Gennaio 1, 2026
DOI: 10.1016/j.clinsp.2026.101105
Fonte documentale originale ↗ - Exploring Molecular Pathways in Metastasis of Breast Cancer Cells to the Brain: Insights from Gene Expression Analysis and Cellular Origins · Ottobre 10, 2023
DOI: 10.4103/jmau.jmau_57_23
Fonte documentale originale ↗ - Clinically actionable genomic alterations in breast cancer brain metastases · Ottobre 1, 2026
DOI: 10.1016/j.esmoop.2026.108551
Fonte documentale originale ↗ - Multigene testing to guide clinical adjuvant decisions in breast cancer: An overview focused on the assessment of the quality of evidence with the grading of recommendations assessment, development and evaluation (GRADE) approach · Settembre 1, 2026
DOI: 10.1177/03936155261471908
Fonte documentale originale ↗
Farmaci e molecole
- Polymer-Metal Nanoparticle Hybrid Systems for Targeted Breast Cancer Therapy: Advances and Clinical Translation. · Agosto 2, 2026
PMID: 42683388 · DOI: 10.7759/cureus.113813
Fonte documentale originale ↗ - An O-prenylated benzylidene-thiazolidinedione derivative suppresses NF-κB signaling in a breast cancer cell line: Possible implications for therapy · Agosto 1, 2026
DOI: 10.1016/j.mrgentox.2026.503951
Fonte documentale originale ↗ - Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab · Settembre 1, 2026
DOI: 10.1200/po-26-00114
Fonte documentale originale ↗ - Recurrence score prediction formula based on immunohistochemistry and biopsy data to predict response to neoadjuvant chemotherapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer · Settembre 11, 2026
DOI: 10.1097/md.0000000000050585
Fonte documentale originale ↗ - Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study · Settembre 1, 2026
DOI: 10.1016/j.annonc.2026.09.002
Fonte documentale originale ↗ - Author correction to “A neutrophil-biomimic platform for eradicating metastatic breast cancer stem-like cells by redox microenvironment modulation and hypoxia-triggered differentiation therapy” [Acta Pharm Sin B 13 (2023) 298–314] · Settembre 1, 2026
DOI: 10.1016/j.apsb.2026.06.039
Fonte documentale originale ↗ - Microproteins as a Hidden Player in Breast Cancer: From Molecular Insights to Therapeutic Potential · Settembre 1, 2026
DOI: 10.1002/cbf.70305
Fonte documentale originale ↗ - Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort · Ottobre 1, 2026
DOI: 10.1016/j.esmoop.2026.108538
Fonte documentale originale ↗ - Microbiome Crosstalk Across Oral, Gut, and Breast Niches: Implications for Breast Cancer Diagnosis, Prevention, and Therapy · Settembre 1, 2026
DOI: 10.1016/j.trsl.2026.09.007
Fonte documentale originale ↗
Biomarcatori e ricerca
- Tislelizumab plus AG regimen for long-term CR in 2 patients with metastatic BRCA-mutation pancreatic cancer: A case report · Dicembre 27, 2024
DOI: 10.1097/md.0000000000040997
Fonte documentale originale ↗ - First-line carboplatin-based chemotherapy may be beneficial for HER2-low advanced breast cancer: A retrospective analysis · Dicembre 27, 2024
DOI: 10.1097/md.0000000000041082
Fonte documentale originale ↗ - Clinical and Biological Predictors of Severe Palbociclib- Induced Neutropenia in Patients with Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: A Retrospective Single-Center Study · Settembre 3, 2026
DOI: 10.59324/ejmhr.2026.4(5).10
Fonte documentale originale ↗ - Post-CDK4/6 inhibitor therapy in HR+/HER2– advanced breast cancer: expanding options and persisting uncertainties · Settembre 11, 2026
DOI: 10.37349/etat.2026.1002400
Fonte documentale originale ↗ - Dissecting the role of inflammatory biomarkers in breast cancer: Insights from Mendelian randomization · Agosto 15, 2025
DOI: 10.1097/md.0000000000043732
Fonte documentale originale ↗